

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Caspase-7 (D2Q3L) Rabbit Antibody

RRID:AB_2687912

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 12827, RRID:AB_2687912

Antibody Information

URL: http://antibodyregistry.org/AB_2687912

Proper Citation: Cell Signaling Technology Cat# 12827, RRID:AB_2687912

Target Antigen: Caspase-7

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W

Antibody Name: Caspase-7 (D2Q3L) Rabbit Antibody

Description: This monoclonal targets Caspase-7

Target Organism: rat, mouse, human

Clone ID: D2Q3L

Antibody ID: AB_2687912

Vendor: Cell Signaling Technology

Catalog Number: 12827

Alternative Catalog Numbers: 12827T, 12827S

Record Creation Time: 20231110T034040+0000

Record Last Update: 20260829T115023+0000

Ratings and Alerts

No rating or validation information has been found for Caspase-7 (D2Q3L) Rabbit Antibody.

No alerts have been found for Caspase-7 (D2Q3L) Rabbit Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. *Cell reports. Medicine*, 7(2), 102578.

Tiburcio PDB, et al. (2025) Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor. *Cell reports. Medicine*, 6(5), 102133.

Ding Z, et al. (2025) MLKL activates the cGAS-STING pathway by releasing mitochondrial DNA upon necroptosis induction. *Molecular cell*, 85(13), 2610.

Paduch R, et al. (2025) Pharmacological and toxicological profiling of JAMC-4/108: targeted induction of apoptosis in human colorectal cancer cells. *The Journal of pharmacology and experimental therapeutics*, 392(11), 103727.

Caggiano R, et al. (2025) Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents. *Neoplasia (New York, N.Y.)*, 59, 101092.

Schiffelers LDJ, et al. (2024) Antagonistic nanobodies implicate mechanism of GSDMD pore formation and potential therapeutic application. *Nature communications*, 15(1), 8266.

He Y, et al. (2024) Deficient tRNA posttranscription modification dysregulated the mitochondrial quality controls and apoptosis. *iScience*, 27(2), 108883.

Tiburcio PDB, et al. (2024) Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor. *bioRxiv : the preprint server for biology*.

Thangavel H, et al. (2024) Adipocyte-released adipomes in Chagas cardiomyopathy: Impact on cardiac metabolic and immune regulation. *iScience*, 27(5), 109672.

Zhang Q, et al. (2024) Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy. *Biochemical pharmacology*, 223, 116198.

Contreras PS, et al. (2023) Beta-coronaviruses exploit cellular stress responses by modulating TFEB and TFE3 activity. *iScience*, 26(3), 106169.

Peng T, et al. (2022) Pathogen hijacks programmed cell death signaling by arginine ADPR-deacylization of caspases. *Molecular cell*, 82(10), 1806.

Rana N, et al. (2022) GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis. *Cell*, 185(2), 283.

Lee HS, et al. (2021) Therapeutic effect of kaempferol on atopic dermatitis by attenuation of T cell activity via interaction with multidrug resistance-associated protein 1. *British journal of pharmacology*, 178(8), 1772.

Donado CA, et al. (2020) A Two-Cell Model for IL-1?? Release Mediated by Death-Receptor Signaling. *Cell reports*, 31(1), 107466.

Doerflinger M, et al. (2020) Flexible Usage and Interconnectivity of Diverse Cell Death Pathways Protect against Intracellular Infection. *Immunity*, 53(3), 533.

Gui F, et al. (2019) A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies. *British journal of pharmacology*, 176(23), 4491.